XOMA (XOMA) Competitors

XOMA (NASDAQ:XOMA) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Is XOMA or INVA more profitable?

Innoviva has a net margin of 18.31% compared to XOMA's net margin of -151.34%. Innoviva's return on equity of 20.84% beat XOMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA	-151.34%	-24.95%	-9.64%
Innoviva	18.31%	20.84%	11.38%

Does the MarketBeat Community favor XOMA or INVA?

XOMA received 138 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 65.96% of users gave XOMA an outperform vote while only 57.58% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
XOMA	Outperform Votes 438 65.96%	Underperform Votes 226 34.04%
Innoviva	Outperform Votes 300 57.58%	Underperform Votes 221 42.42%

Which has better earnings & valuation, XOMA or INVA?

Innoviva has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA	$4.76M	66.23	-$40.83M	-$3.48	-7.69
Innoviva	$310.46M	3.75	$179.72M	$0.69	26.93

Do institutionals and insiders believe in XOMA or INVA?

95.9% of XOMA shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 7.2% of XOMA shares are owned by company insiders. Comparatively, 1.7% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Do analysts rate XOMA or INVA?

XOMA currently has a consensus target price of $81.50, indicating a potential upside of 204.56%. Given XOMA's higher probable upside, equities research analysts clearly believe XOMA is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Innoviva	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer XOMA or INVA?

In the previous week, XOMA had 4 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for XOMA and 1 mentions for Innoviva. Innoviva's average media sentiment score of 1.70 beat XOMA's score of 0.17 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, XOMA or INVA?

XOMA has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Summary

Innoviva beats XOMA on 9 of the 17 factors compared between the two stocks.